Doxorubicin (Dox) is an anthracycline antitumor agent with the disadvantages of cumulative
cardiotoxicity, short retention time, and rapid excretion. A liposomal formulation of …

Purpose The folate receptor (FR) is overexpressed in a broad spectrum of malignant tumors
and represents an attractive target for selective delivery of anti-cancer agents to FR …

Doxorubicin (DOX) loaded liposomes have been used and studied in the last decades due
to the significant decrease in DOX induced cardiac and systemic toxicity relative to …

Among all available lipid based nanoparticulate systems, the success of liposomal drug
delivery system is evident by the number of liposomal products available in the market or …

Purpose. The expression of folate receptor (FR) is amplified in many types of human
cancers. Previously, FR-targeted liposomal doxorubicin (fL-DOX) has been shown to exhibit …

Background: Ligand-mediated liposomes targeting folate receptors (FRs) that are
overexpressed on the surface of tumor cells may improve drug delivery. However, the …

We previously showed that folate liposomes of 5FU made from
Dipalmitoylphosphatidylcholine (DPPC) induced cell death in HT-29 and HeLa cells more …

Long circulating pH-sensitive liposomes have been shown to effectively deliver doxorubicin
(DOX) to tumors and reduce its toxic effects. Folic acid receptors are upregulated in a wide …

Folate polyethylene glycol-cholesterol hemisuccinate (folate-PEG-CHEMS) is a novel folate
ligand firstly synthesized by our group and demonstrated good stability and potential …

Tumour cell-targeted liposomal delivery has the potential to enhance the therapeutic efficacy
and reduce the toxicity of anticancer agents. Folate receptor (FR) expression is frequently …